1 Department of Internal Medicine, Faculty of Health Sciences, Universidad Libre, Barranquilla, Colombia.
2 Department of Cardiology, Faculty of Health Sciences, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia.
Review Article
World Journal of Advanced Research and Reviews, 2023, 18(03), 1098–1105
Article DOI: 10.30574/wjarr.2023.18.3.1187
Received on 09 May 2023; revised on 19 June 2023; accepted on 21 June 2023
Atrial fibrillation is the most common cardiac arrhythmia in the world, with an estimated prevalence of 2 to 4%, and represents a high burden of disease worldwide. It is defined as a supraventricular tachyarrhythmia with loss of atrial activity, diagnosed by specific electrocardiographic findings. Its classification is clearly defined, based on the form of presentation, duration and the resolution of the episodes. One of the pillars in the treatment of this pathology is anticoagulant therapy, which represents a challenge due to the heterogeneity of the patients, however there are specific situations such as chronic kidney disease, oncological diseases and liver disease, where the situation becomes even more complex, however different studies have been carried out in which the best strategies based on scientific evidence have been proposed for the approach of these patients in special situations.
Atrial Fibrillation; Anticoagulation; Chronic Kidney Disease; Anticoagulants.
Preview Article PDF
Erick Alexander Cabrera Estrada, Epitafio Rafael Mestre Sequeda, John Alexander Caballero RÃos, Carlos José Brito Jacome, Olga Virginia Jacquin Serna and Gabriela Lucia Lara Barreto. Anticoagulation in atrial fibrillation: Special scenarios. World Journal of Advanced Research and Reviews, 2023, 18(3), 1098-1105. Article DOI: https://doi.org/10.30574/wjarr.2023.18.3.1187